Abstract
Therapeutic antibodies have evolved into an important drug class and have achieved considerable success in combating cancers and autoimmune diseases. Although their potential in the treatment of viral infections has not yet been fully explored, recently established approaches have the potential to aid the development of HIV specific antibody therapies. Antibody engineering has led to improvements in antibody isolation and increases in antibody efficacy and potency. Strategies have been developed to tailor Fc recruitment of effector functions, and conjugation of monoclonals to toxins endows them with the ability to mediate destruction of specific target cells. These technical advances introduce the possibility of designing a therapy to target and clear cells infected with a broad range of HIV strains and recommend some hypothetical clinical settings in which advanced antibody therapeutics could be employed in prophylaxis or therapy for HIV infection.
Keywords: HIV, AIDS, therapeutic antibodies, passive immunization, infectious diseases, cancers, autoimmune diseases, viral infections, prophylaxis, neutralizing antibodies, anti-HIV drug, antiretroviral therapy, polyclonal immunoglobulin, respiratory syncytial virus, palivizumab, simian immunodeficiency virus, –, HIV chimera, Cell-mediated virus inhibition, cellular-phagocytosis, complement-mediated cytotoxicity, gp41, gp120, immunotoxin, CD4-MHC II, Ibalizumab, Human Genome Sciences, Natalizumab, Efalizumab, Half Life, Conjugating Antibodies, duocarmycin, calicheamicin, PEGylation, Camelids, Chondrichthyes
Current Pharmaceutical Design
Title: Therapeutic Antibodies in HIV Treatment - Classical Approaches to Novel Advances
Volume: 16 Issue: 33
Author(s): Irene A. Abela, Lucy Reynell and Alexandra Trkola
Affiliation:
Keywords: HIV, AIDS, therapeutic antibodies, passive immunization, infectious diseases, cancers, autoimmune diseases, viral infections, prophylaxis, neutralizing antibodies, anti-HIV drug, antiretroviral therapy, polyclonal immunoglobulin, respiratory syncytial virus, palivizumab, simian immunodeficiency virus, –, HIV chimera, Cell-mediated virus inhibition, cellular-phagocytosis, complement-mediated cytotoxicity, gp41, gp120, immunotoxin, CD4-MHC II, Ibalizumab, Human Genome Sciences, Natalizumab, Efalizumab, Half Life, Conjugating Antibodies, duocarmycin, calicheamicin, PEGylation, Camelids, Chondrichthyes
Abstract: Therapeutic antibodies have evolved into an important drug class and have achieved considerable success in combating cancers and autoimmune diseases. Although their potential in the treatment of viral infections has not yet been fully explored, recently established approaches have the potential to aid the development of HIV specific antibody therapies. Antibody engineering has led to improvements in antibody isolation and increases in antibody efficacy and potency. Strategies have been developed to tailor Fc recruitment of effector functions, and conjugation of monoclonals to toxins endows them with the ability to mediate destruction of specific target cells. These technical advances introduce the possibility of designing a therapy to target and clear cells infected with a broad range of HIV strains and recommend some hypothetical clinical settings in which advanced antibody therapeutics could be employed in prophylaxis or therapy for HIV infection.
Export Options
About this article
Cite this article as:
A. Abela Irene, Reynell Lucy and Trkola Alexandra, Therapeutic Antibodies in HIV Treatment - Classical Approaches to Novel Advances, Current Pharmaceutical Design 2010; 16 (33) . https://dx.doi.org/10.2174/138161210794079245
DOI https://dx.doi.org/10.2174/138161210794079245 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Therapeutic Use of Vitamin D and its Analogues in Autoimmunity
Recent Patents on Inflammation & Allergy Drug Discovery Autoimmunity-Inducing Metals (Hg, Au and Ag) Modulate Mast Cell Signaling, Function and Survival
Current Pharmaceutical Design Metformin - The Drug for the Treatment of Autoimmune Diseases; A New Use of a Known Anti-Diabetic Drug
Current Topics in Medicinal Chemistry Control of Autoimmune Diseases by the B7-CD28 Family Molecules
Current Pharmaceutical Design A New Drug Candidate (GEMSP) for Multiple Sclerosis
Current Medicinal Chemistry The Use of Mesenchymal Stem Cells for the Treatment of Autoimmunity: From Animals Models to Human Disease
Current Drug Targets Novel Topical Nanocarriers for Treatment of Psoriasis: An Overview
Current Pharmaceutical Design Properdin and Complement Activation: A Fresh Perspective
Current Drug Targets Targeting T-Cell Adhesion Molecules for Drug Design
Current Pharmaceutical Design Gastrointestinal Immune System and Brain Dialogue Implicated in Neuroinflammatory and Neurodegenerative Diseases
Current Molecular Medicine NF-κB in Type 1 Diabetes
Inflammation & Allergy - Drug Targets (Discontinued) Are B Cells a Potential Target for Therapeutic Intervention in the Classical T Cell-Mediated Autoimmune Disease Type 1 Diabetes?
Inflammation & Allergy - Drug Targets (Discontinued) Genetics and Ulcerative Colitis: What are the Clinical Implications?
Current Drug Targets Discovery of Small Molecule Inhibitors for Prevention of Complement- Mediated Immune Hemolysis
Drug Design Reviews - Online (Discontinued) Estrogens as Potential Therapeutic Agents in Multiple Sclerosis
Central Nervous System Agents in Medicinal Chemistry The Link Between CD6 and Autoimmunity: Genetic and Cellular Associations
Current Drug Targets Current and Potential Agents for the Treatment of Alopecia Areata
Current Pharmaceutical Design Vitamin D Analogs: Mechanism of Action and Therapeutic Applications
Current Medicinal Chemistry Lipid-Based Nanocarriers for RNA Delivery
Current Pharmaceutical Design Introduction from Editor-in-Chief
Current Rheumatology Reviews